

AROMASIN[®]

(Exemestane)

1. NAME OF THE MEDICINAL PRODUCT

AROMASIN[®]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 25 mg exemestane.

3. PHARMACEUTICAL FORM

Coated tablets

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

AROMASIN[®] is indicated for the adjuvant treatment of post-menopausal women with estrogen-receptor positive or unknown early breast cancer to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer.^{23,24}

AROMASIN[®] is indicated for the first line treatment of hormone-receptor positive advanced breast cancer (ABC) in women with natural or induced post-menopausal status.²⁹

AROMASIN[®] is indicated for the second-line treatment of ABC in women with natural or induced post-menopausal status whose disease has progressed following anti-estrogen therapy alone.^{1,2,3}

AROMASIN[®] is also indicated for the third-line treatment in post-menopausal women with ABC whose disease has progressed following multiple hormonal therapies.^{4,5,6}

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

Adult and Elderly Patients

The recommended dose of AROMASIN[®] is one 25-mg tablet to be taken once daily, preferably after a meal.

In patients with early breast cancer, treatment with AROMASIN[®] should continue until completion of five years of adjuvant endocrine therapy, or until local or distant recurrence or new contralateral breast cancer.^{23,24}

In patients with advanced breast cancer, treatment with exemestane should continue until tumor progression is evident.

Hepatic or Renal Insufficiency

No dose adjustments are required for patients with hepatic or renal insufficiency.^{21,22}

4.3. CONTRAINDICATIONS

Exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Because of its mode of action, exemestane should not be administered to women with premenopausal endocrine status.

Exemestane should not be coadministered with estrogen-containing products as these would negate its pharmacological action.

As exemestane is a potent estrogen lowering agent, reductions in bone mineral density can be anticipated. During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally assessed by bone densitometry at the commencement of treatment. Patients treated with exemestane should be carefully monitored and treatment for osteoporosis should be initiated as appropriate.^{30,31}

Routine assessment of 25 hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be considered, due to the high prevalence of severe deficiency associated in women with early breast cancer (EBC). Women with Vitamin D deficiency should receive supplementation with Vitamin D.³⁶

4.5. INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION

In vitro evidence showed that the drug is metabolized through cytochrome P450 (CYP) 3A4¹² and aldoketoreductases^{13,14} and does not inhibit any of the major CYP isoenzymes. In a clinical pharmacokinetic study, the specific inhibition of CYP3A4 by ketoconazole showed no significant effects on the pharmacokinetics of exemestane.¹⁵

Although pharmacokinetic effects were observed in a pharmacokinetic interaction study with rifampicin, a potent CYP3A4 inducer, the pharmacologic activity (i.e., estrogen suppression) was not affected, and a dosage adjustment is not required.^{16,17}

4.6. FERTILITY, PREGNANCY AND LACTATION

Pregnancy

Exemestane should not be used in women who are or may become pregnant because it may cause harm to the fetus. Studies in animals have shown reproductive toxicity (See section 5.3. **Preclinical data study**)^{7,8,9}

Lactation

It is not known whether exemestane is excreted into human milk. Exemestane should not be used in women who are lactating.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effect of exemestane on the ability to drive and use machinery has not been systematically evaluated.

4.8. UNDESIRABLE EFFECTS

Clinical Trials

AROMASIN[®] was generally well tolerated across all studies and in the clinical studies, conducted with AROMASIN[®] 25 mg/day, adverse events were usually mild to moderate.^{1,2,3,4,5,6,10,11}

The discontinuation rate due to adverse events was 7.4% in patients with early breast cancer receiving adjuvant treatment with exemestane following initial adjuvant tamoxifen therapy. The most commonly reported adverse reactions were hot flushes (22%), arthralgia (18%), and fatigue (16%).³⁰

The discontinuation rate due to adverse events was 2.8% in the overall patient population with advanced breast cancer. The most commonly reported adverse reactions were hot flushes (14%) and nausea (12%).

Most adverse reactions can be attributed to the normal pharmacological consequences of estrogen deprivation (e.g., hot flushes).^{1,2,3,4,5,6,10,11,23,24,30}

The reported adverse reactions^{1,2,3,4,5,6,10,11,23,24,30} are listed below by MedDRA System Organ Class and by frequency. Frequencies are defined as: Very common ($\geq 1/10$), Common ($\geq 1/100$ to $< 1/10$), Uncommon ($\geq 1/1,000$ to $< 1/100$), Rare ($\geq 1/10,000$ to $< 1/1,000$).³⁹

<i>Metabolism and nutrition disorders:</i>	
<i>Common</i>	Anorexia
<i>Psychiatric disorders:</i>	
<i>Very common</i>	Depression, insomnia
<i>Nervous system disorders:</i>	
<i>Very common</i>	Headache, dizziness
<i>Common</i>	Carpal tunnel syndrome

<i>Vascular disorders:</i>	
<i>Very common</i>	Hot flushes
<i>Gastrointestinal disorders:</i>	
<i>Very common</i>	Abdominal pain ,nausea
<i>Common</i>	Vomiting, diarrhoea, constipation, dyspepsia
<i>Hepatobiliary disorders:</i>	
<i>Very common</i>	Hepatic enzyme increased, blood bilirubin increased, blood alkaline phosphatase increased ^{3,23,24,29,30}
<i>Skin and subcutaneous tissue disorders:</i>	
<i>Very common</i>	Increased sweating
<i>Common</i>	Alopecia, rash,
<i>Musculoskeletal and bone disorders:</i>	
<i>Very common</i>	Joint and musculoskeletal pain ^(*)
<i>Common</i>	Fracture ³⁰ , osteoporosis
<i>General disorders and administration site conditions:</i>	
<i>Very common</i>	Pain, fatigue
<i>Common</i>	Oedema peripheral

(*) Includes: arthralgia, and less frequently pain in limb, osteoarthritis, back pain, arthritis, myalgia and joint stiffness.

In patients with advanced breast cancer, an occasional decrease in lymphocytes has been observed in approximately 20% of patients receiving AROMASIN[®], particularly in patients with pre-existing lymphopenia. However, mean lymphocyte values in these patients did not change significantly over time and no corresponding increase in viral infections was observed.^{1,2,3,4,5,6,29}

In the early breast cancer trial, the frequency of ischemic cardiac events in the exemestane and tamoxifen treatment arms was 4.5% vs. 4.2%, respectively.³⁰ No significant difference was noted for any individual cardiovascular event including hypertension (9.9% vs. 8.4%),³⁰ myocardial infarction (0.6% vs. 0.2%)³³ and cardiac failure (1.1% vs. 0.7%).³³

In the early breast cancer trial, gastric ulcer was observed at a slightly higher frequency in the exemestane arm compared to tamoxifen (0.7% vs. <0.1%). The majority of patients on exemestane with gastric ulcer received concomitant treatment with non-steroidal anti-inflammatory agents and/or had a prior history.³⁰

Post-marketing Experience:

Immune system disorders

Uncommon: Hypersensitivity³⁶

Nervous system disorders

Common: Paraesthesia³⁸

Hepatobiliary disorders

Rare: Hepatitis, hepatitis cholestatic³⁴

Skin and subcutaneous tissue disorders

Common: Urticaria, pruritus³⁶

Rare:

Acute generalised exanthematous pustulosis³⁸

4.9. OVERDOSE

Clinical trials have been conducted with exemestane given up to 800 mg in a single dose to healthy female volunteers and up to 600 mg daily to post-menopausal women with advanced breast cancer; these dosages were well tolerated.^{10,18} In rats and dogs, lethality was observed after single oral doses equivalent to 2000 and 4000 times, respectively, the recommended human dose on a mg/m² basis.^{19,20} There is no specific antidote to overdosage and treatment must be symptomatic.

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: steroidal aromatase inhibitor; anti-neoplastic agent

Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, estrogens are produced primarily from the conversion of androgens into estrogens through the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in post-menopausal women. In post-menopausal women, orally administered exemestane significantly lowered serum estrogen concentrations starting from a 5 mg dose, reaching maximal suppression (>90%) with a dose of 10-25 mg. In post-menopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%.

Exemestane does not possess any progestogenic or estrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, exemestane had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway. These findings indicate that glucocorticoid or mineralocorticoid replacements are not warranted.

A slight non-dose-dependent increase in serum LH and FSH levels has been observed even at low doses. However, this pharmacological class effect is expected and probably results from feedback at

the pituitary level due to the reduction in estrogen levels that stimulate the pituitary secretion of gonadotropins (also in post-menopausal women).

Clinical Studies

Adjuvant Treatment of Early Breast Cancer

In a multicenter, randomized, double-blind study (Intergroup Exemestane Study [IES]), conducted in 4724 post-menopausal patients with estrogen-receptor-positive or unknown primary breast cancer, patients who had remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years, were randomized to receive 3 to 2 years of exemestane (25 mg/day) or tamoxifen (20 or 30 mg/day) to complete a total of 5 years of hormonal therapy.²³

35-Month Median Follow-up (Primary efficacy analysis)

After a median duration of therapy of about 27 months and a median follow-up of about 35 months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in disease-free survival (DFS) compared with continuation of tamoxifen therapy. Analysis showed that over the observed study period exemestane reduced the risk of breast cancer recurrence by 31% compared with tamoxifen (hazard ratio 0.69; $p = 0.00003$). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.²³

Exemestane also significantly reduced the risk of contralateral breast cancer (hazard ratio 0.32, $p = 0.0034$) and significantly prolonged breast cancer free survival (hazard ratio 0.65, $p < 0.00001$) and distant recurrence free survival (hazard ratio 0.70, $p = 0.00083$).

At the time of analysis, overall survival was not significantly different in the two groups with 116 deaths occurring in the exemestane group and 137 in the tamoxifen group (hazard ratio 0.86, $p = 0.23$).²³

A lower incidence of other second (non-breast) primary cancers was observed in exemestane-treated patients versus tamoxifen-treated patients (2.2% vs. 3.5%).²³

52-Month Median Follow-up

After a median duration of therapy of about 30 months and a median follow-up of about 52 months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in DFS compared with continuation of tamoxifen therapy. Analysis showed that over the observed study period exemestane reduced the risk of breast cancer recurrence by 24% compared with tamoxifen (hazard ratio 0.76, $p = 0.00015$). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.

Exemestane also significantly reduced risk of contralateral breast cancer (hazard ratio 0.57, $p = 0.04158$), significantly prolonged breast cancer-free survival (hazard ratio 0.76, $p = 0.00041$), and distant recurrence-free survival (hazard ratio 0.83, $p = 0.02621$).

In the whole study population, a trend for improved overall survival was observed for exemestane (222 deaths) compared to tamoxifen (262 deaths) with a hazard ratio 0.85 (log rank test: $p = 0.07362$),

representing a 15% reduction in the risk of death in favor of exemestane. However, for the subset of patients with estrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.83 (log-rank test: $p = 0.04250$), representing a clinically and statistically significant 17% reduction in the risk of dying.

In the whole study population, a statistically significant 23% reduction in the risk of dying (hazard ratio for overall survival 0.77; Wald chi square test: $p = 0.0069$) was observed for exemestane compared to tamoxifen when adjusting for the pre specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).

A lower incidence of other second (non-breast) primary cancers was observed in exemestane-treated patients compared with tamoxifen only-treated patients (3.6% vs. 5.3%).³⁰

Results from an endometrial sub-study indicate that after 2 years of treatment there was a median 33% reduction of endometrial thickness in the exemestane-treated patients compared with no notable variation in the tamoxifen-treated patients. Endometrial thickening, reported at the start of study treatment, was reversed to normal for 54% of patients treated with exemestane.³²

87-Month Median Follow-up

After a median duration of therapy of about 30 months and a median follow-up of about 87 months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in DFS compared with continuation of tamoxifen therapy. Analysis showed that over the observed study period exemestane reduced the risk of breast cancer recurrence by 16% compared with tamoxifen (hazard ratio 0.84, $p = 0.002$). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.³⁵

Exemestane also significantly prolonged breast cancer-free survival (hazard ratio 0.82, $p = 0.00263$), and distant recurrence-free survival (hazard ratio 0.85, $p = 0.02425$). Exemestane also reduced risk of contralateral breast cancer; however, the effect was no longer statistically significant (hazard ratio 0.74, $p = 0.12983$). In the whole study population, a trend for improved overall survival was observed for exemestane (373 deaths) compared to tamoxifen (420 deaths) with a hazard ratio 0.89 (log rank test: $p = 0.08972$), representing an 11% reduction in the risk of death in favor of exemestane. However, for the subset of patients with estrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.86 (log-rank test: $p = 0.04262$), representing a clinically and statistically significant 14% reduction in the risk of dying.³⁵

In the whole study population, a statistically significant 18% reduction in the risk of dying (hazard ratio for overall survival 0.82; Wald chi square test: $p = 0.0082$) was observed for exemestane compared to tamoxifen when adjusting for the pre specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).³⁵

A lower incidence of other second (non-breast) primary cancers was observed in exemestane-treated patients compared with tamoxifen only-treated patients (5.6% vs. 7.6%).³⁵

Results from a bone sub-study indicate that treatment with exemestane for 2 to 3 years following 3 to 2 years of tamoxifen treatment increased bone loss while on treatment (mean % change from baseline for BMD at 36 months: -3.37 [spine], -2.96 [total hip] for exemestane and -1.29 [spine], -2.02 [total hip], for tamoxifen).

However by the end of the follow-up period there were minimal differences between the treatment arms in the change in BMD from baseline, with the tamoxifen arm having slightly greater final reductions in BMD at all sites (mean % change from baseline for BMD at 24 months post-treatment -2.17 [spine], -3.06 [total hip] for exemestane and -3.44 [spine], -4.15 [total hip] for tamoxifen).³⁷

119-Month Final Follow-Up

After a median duration of therapy of about 30 months and a median follow-up of about 119 months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in DFS compared with continuation of tamoxifen therapy. Analysis showed that over the observed study period exemestane reduced the risk of breast cancer recurrence by 14% compared with tamoxifen (hazard ratio 0.86, $p = 0.00393$). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.^{40,43}

Exemestane also significantly prolonged breast cancer-free survival (hazard ratio 0.83, $p < 0.00152$), and distant recurrence-free survival (hazard ratio 0.86, $p = 0.02213$). Exemestane also reduced risk of contralateral breast cancer; however, the effect was no longer statistically significant (hazard ratio 0.75, $p = 0.10707$).^{40,43}

In the whole study population, overall survival was not statistically different between the two groups with 467 deaths (19.9%) occurring in the exemestane group and 510 deaths (21.5%) in the tamoxifen group (hazard ratio 0.91, $p = 0.15737$, not adjusted for multiple testing). For the subset of patients with estrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.89 (log-rank test: $p = 0.07881$), in the exemestane group relative to the tamoxifen group.^{40,43}

In the whole study population, a statistically significant 14% reduction in the risk of dying (hazard ratio for OS 0.86; Wald chi square test: $p = 0.0257$) was observed for exemestane compared with tamoxifen when adjusting for the pre specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).^{40,43}

A lower incidence of other second (non-breast) primary cancers was observed in exemestane-treated patients compared with tamoxifen only-treated patients (9.9% vs. 12.4%).^{40,43}

Treatment of Advanced Breast Cancer

In a phase 3 study conducted by the EORTC (European Organization for Research and Treatment of Cancer), exemestane was compared to tamoxifen as first-line treatment of advanced breast cancer. Results indicated that patients in the exemestane treatment group had a longer median Progression Free Survival (PFS) time compared to tamoxifen (9.9 months vs. 5.8 months) with a hazard ratio of 0.84 in favor of exemestane ($p = 0.028$ by Wilcoxon test; $p = 0.121$ by log-rank test). Exemestane-treated patients also had a higher objective tumor response rate compared to tamoxifen (44% vs. 31%).²⁹

In a randomized peer reviewed controlled clinical trial, exemestane at the daily dose of 25 mg demonstrated statistically significant prolongation of survival, Time to Progression (TTP), Time to Treatment Failure (TTF) as compared to a standard hormonal treatment with megestrol acetate in post-menopausal patients with advanced breast cancer that had progressed following, or during, treatment with tamoxifen either as adjuvant therapy or as first-line treatment for advanced disease.

5.2. PHARMACOKINETIC PROPERTIES

Absorption

After oral administration of exemestane tablets, the drug is absorbed rapidly. The fraction of the dose absorbed from the gastrointestinal tract is high. The absolute bioavailability in humans is unknown, although it is anticipated to be limited by an extensive first pass effect. A similar effect resulted in an absolute bioavailability in rats and dogs of 5%. After a single dose of 25 mg, maximum plasma levels of 17 ng/mL are reached by 2 hours. Exemestane pharmacokinetics are linear time independent and do not demonstrate unexpected accumulation with repeated administration. The terminal elimination half-life of exemestane is approximately 24 hr. Concomitant administration with food increases exemestane bioavailability by approximately 40%.

Distribution

The volume of distribution of exemestane, not corrected for the oral bioavailability (V/F), is ca 20,000 L. Binding to plasma proteins is 90% and is concentration independent. Exemestane and its metabolites do not bind to red blood cells.

Metabolism and Excretion

Exemestane is metabolized via oxidation of the methylene moiety on the 6 position by CYP 3A4 and/or reduction of the 17-keto group by aldoketoreductase followed by conjugation. The clearance of exemestane not corrected for the oral bioavailability (CL/F) is ca 500 L/h. Exemestane metabolites are either inactive or demonstrate markedly lower aromatase inhibition than the parent compound. Following the administration of a 14C-labeled exemestane dose, approximately equal amounts (ca 40%) of drug-derived radioactivity were eliminated in urine and feces within 1 week. Between 0.1 to 1% of the radioactive dose was excreted in the urine as unchanged 14C-labeled exemestane.

Special populations

Age

No significant correlation between exemestane systemic exposure and age has been observed.

Renal insufficiency

In patients with severe renal impairment (CLcr <30 mL/min) the systemic exposure to exemestane was 2-times higher compared with healthy volunteers.

Given the safety profile of exemestane, no dose adjustment is considered necessary.

Hepatic insufficiency

In patients with moderate or severe hepatic impairment the exposure of exemestane is 2-3-fold higher compared with healthy volunteers. Given the safety profile of exemestane, no dose adjustment is considered necessary.

5.3. PRECLINICAL SAFETY DATA

Acute toxicity

The acute oral toxicity of exemestane is low with LD₅₀ in rodents >2000 mg/kg and the compound was well tolerated in dogs up to 1000 mg/kg.^{19,20}

Chronic toxicity

In repeated-dose toxicity studies, the no-toxic-effect levels after 1 year's treatment were 50 mg/kg/day in rats and 30 mg/kg/day in dogs, which yielded systemic exposure approximately 3 to 6 times higher compared to the exposure in humans at 25 mg/day. In all species tested and in both sexes, there were effects on reproductive and accessory organs which were related to the pharmacological activity of exemestane. Other toxicological effects (on liver, kidney or central nervous system) were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.

Mutagenicity

Exemestane was not genotoxic in bacteria (Ames test), in V79 Chinese hamster cells, in rat hepatocytes or in the mouse micronucleus assay. Although exemestane was clastogenic in lymphocytes *in vitro*, it was not clastogenic in two *in vivo* studies.

Carcinogenicity

In a two-year carcinogenicity study in female rats, no treatment-related tumors were observed. In male rats the study was terminated on week 92, because of early death by chronic nephropathy. In a two-year carcinogenicity study in mice, an increase in the incidence of hepatic neoplasms in both genders was observed at the intermediate and high doses (150 and 450 mg/kg/day). This finding is considered to be related to the induction of hepatic microsomal enzymes, an effect observed in mice but not in clinical studies. An increase in the incidence of renal tubular adenomas was also noted in male mice at the high dose (450 mg/kg/day). This change is considered to be species- and gender-specific and occurred at a dose which represents 63-fold greater exposure than occurs at the human therapeutic dose. None of these observed effects is considered to be clinically relevant to the treatment of patients with exemestane.^{26,27,28}

Reproductive Toxicity

In animal reproduction studies in rats and rabbits, exemestane was embryotoxic, fetotoxic, and abortifacient. When rats were administered exemestane from 14 days prior to mating until either days 15 or 20 of gestation, and resuming for the 21 days of lactation, an increase in placental weight was seen at 4 mg/kg/day (approximately 1.5 times the recommended human daily dose on a mg/m² basis). Increased resorptions, reduced number of live fetuses, decreased fetal weight, retarded ossification, prolonged gestation and abnormal or difficult labor was observed at doses equal to or greater than 20 mg/kg/day (approximately 7.5 times the recommended human daily dose on a mg/m² basis). Daily doses of exemestane given to rabbits during organogenesis caused a decrease in placental weight at 90 mg/kg/day (approximately 70 times the recommended human daily dose on a mg/m² basis) and, in the presence of maternal toxicity, abortions, an increase in resorptions, and a reduction in fetal body weight were seen at 270 mg/kg/day (approximately 210 times the recommended human dose on a mg/m² basis). No malformations were noted when exemestane was administered to pregnant rats or rabbits during the organogenesis period at doses up to 810 and 270 mg/kg/day, respectively (approximately 320 and 210 times the recommended human dose on a mg/m² basis, respectively).^{7,8,9,42}

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Not available

6.2. INCOMPATIBILITIES

Not available

6.3. SHELF LIFE

36 months

6.4. SPECIAL PRECAUTIONS FOR STORAGE

Do not store above 30°C.

Avoid exposure to heat, sunlight and moisture.

6.5. NATURE AND CONTENTS OF CONTAINER

AROMASIN[®] (exemestane) 25 mg tablet is available as the pack of 15's in blister strip.

6.6. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.

Aromasin/LPD/PK-03

According to CDS V 10.0 dated September 07, 2017; Supersedes CDS V 9.0 dated January 24, 2017

Manufactured by:

Pfizer Pakistan limited

B-2, S.I.T.E Karachi Pakistan.

7. REFERENCES

1. Massimini G, Polli A, Mariani O, di Salle E. *Antitumor efficacy of exemestane in postmenopausal patients with metastatic breast cancer, failing to tamoxifen.* (Final Report of the Study 93OEXE010). Pharmacia & Upjohn Internal Report PNU-155971/9850244, August 18, 1998.
2. Arkhipov A, Tiffany JK, Whaley FS, et al. *Efficacy trial of FCE 24304 (exemestane, 6-methylenandrosta-1,4-diene-3,17-dione) in the treatment of postmenopausal patients with metastatic breast cancer failing tamoxifen.* (Final Report of the Trial 120002-999). Pharmacia & Upjohn Internal Report PNU-155971/9850170; August 6, 1998.
3. Fowst C, Polli A, di Salle E, et al. *Exemestane versus megestrol acetate in postmenopausal patients with metastatic breast cancer, failing tamoxifen: a phase III, double-blind, randomized, parallel group, comparative study.* (Report of trial 94OEXE018 as of August 31, 1998). Pharmacia & Upjohn Internal Report PNU-155971/9850243; October 1998.
4. Arkhipov A, Royer M, Tiffany JK, et al. *Antitumor efficacy of exemestane in postmenopausal women with metastatic breast cancer failing Tamoxifen and Megace* (Interim Report of the Trial 95OEXE022). Pharmacia & Upjohn Internal Report PNU-155971/9850172, October 19, 1998.
5. Fowst C, Polli A, Massimini G, et al. *Antitumor efficacy of exemestane in postmenopausal patients with metastatic breast cancer, failing non-steroidal aromatase inhibitors.* (Final Report of the Trial 94-OEXE 017) Pharmacia & Upjohn Internal Report PNU-155971/9850169 August 24, 1998.
6. Arkhipov A, Tiffany JK, Whaley FS, et al. *Antitumor efficacy of FCE 24304 (exemestane [PNU 155971]) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and Megace™.* (Final Report of the Trial 120003-999) Pharmacia & Upjohn Internal Report PNU-155971/9850171; July 10, 1998.
7. Savary MH. *FCE 24304: Assessment of possible embryotoxic or teratogenic effects in rabbits by oral route.* Farmitalia Carlo Erba Internal Report FCE 24304/411i; April 30, 1991. Plus No. 1 Addendum.
8. Hoberman AM. *Fertility and general reproduction study (including a "behavioral" postnatal evaluation) of FCE 24304 administered orally via gavage to Crl: CD(R) BR VAF/Plus (R) female rats. (Segment I evaluation) + Amendment.* Farmitalia Carlo Erba Internal Report FCE 24304/417i; February 9, 1993.
9. Bussi R. *Teratogenesis study of FCE 24304 by oral route in rats.* Farmitalia Carlo Erba Internal Report FCE 24304/414i; April 15, 1992.
10. Piscitelli G, Massimini G, Polli A, Lanzalone S, di Salle E, Ornati G. *Dose finding study of exemestane in postmenopausal advanced breast cancer: single daily dose.* (Final Report of study 90-OEXE 004).

Pharmacia & Upjohn Internal Report PNU-155971/9750148; December 1, 1997 + Amendment of June 24, 1998 (Report N. 9850234).

11. Pacciarini MA, Piscitelli G. *Endocrinological evaluation of exemestane (PNU-155971; FCE 2430) 4 in post menopausal patients with metastatic breast cancer receiving different doses.* (Final report of the study 91-OEXE 007). Pharmacia & Upjohn Internal Report PNU-155971/9650095; September, 1997 + Amendment of June 25, 1998 (Report N. 9850236).
12. Pichard L. *Identification of the form(s) of cytochrome(s) P450 involved in the oxidative metabolism of FCE 24304 in human liver.* Pharmacia & Upjohn Internal Report PNU-155971/9750052; January 1997.
13. Cocchiara G, Allievi C. *Metabolism of FCE 24304 in human urine after oral administration of [14C]-FCE 24304 (100 mg) to healthy postmenopausal subjects* (Addendum I to the study report FCE 24304/603i). Pharmacia Internal Report FCE 24304/9650139, March 1996.
14. Marrari P, Broutin F, Stefanini P, Spinelli R. *Plasma levels of FCE 24304 and its metabolite FCE 25071 after a single oral administration of [14C]-FCE 24304 to four healthy postmenopausal volunteers* (Addendum 2 to the study report FCE 24304/603i). Pharmacia Internal Report FCE-24304/9650141 A2i, March 1996.
15. Jannuzzo MG, Böttiger Y, Spinelli R, Broutin F. *Study of the possible involvement of CYP 3A4 in exemestane metabolism in healthy postmenopausal volunteers* (Final Report of the Trial 95-OEXE 028). Pharmacia & Upjohn Internal Report PNU-155971/9750150; December 19, 1997.
16. Jannuzzo MG, Sarapa N, Polli A, Poggesi I, Rocchetti M, Spinelli R. *A study to investigate a possible pharmacokinetic interaction between a single oral dose of exemestane 25 mg tablets and rifampicin 600 mg daily administered for two weeks to healthy postmenopausal women.* Pharmacia & Upjohn Internal Report 971-ONC-0028-076; 5 September 2001.
17. Jannuzzo MG, Spinelli R, Poggesi I, Rocchetti M. Addendum I: *“Additional Pharmacokinetic and Pharmacodynamic Analyses” To study report: A study to investigate a possible pharmacokinetic interaction between a single oral dose of exemestane 25 mg tablets and rifampicin 600 mg daily administered for two weeks to healthy postmenopausal women.* Addendum I to Pharmacia & Upjohn Internal Report 971-ONC-0028-076; 28 February 2002.
18. Zurlo MG, Beretta E, di Salle E, Coombes RC, Evans TRJ, Ornati G. *Phase I single oral dose tolerance of exemestane (FCE 24304) in healthy volunteers: Clinical Part.* (Protocol MI MAD DRFI 001). Farmitalia Carlo Erba Internal Report FCE 24304/602i; June 1991.
19. Antongiovanni V. *Acute oral and intraperitoneal toxicity of FCE 24304 in rats.* Farmitalia Carlo Erba Internal Report FCE 24304/403i; April 14, 1988.
20. Lux B. *Study of the acute toxicity of compound FCE 24304 given orally to the beagle.* Farmitalia Carlo Erba Internal Report FCE 24304/401i; November 23, 1987.
21. Jannuzzo MG, Spinelli R, Fiorentini F. *The effect of varying degrees of hepatic impairment on the pharmacokinetics of exemestane in postmenopausal volunteers: preliminary results.* (Trial 95 OEXE 015). Pharmacia & Upjohn Internal Report PNU-155971/9850242; October 19, 1998.

22. Jannuzzo MG, Spinelli R. *The effect of varying degrees of renal impairment on the pharmacokinetics of exemestane in postmenopausal volunteers: preliminary results.* (Trial 95 OEXE 016). Pharmacia & Upjohn Internal Preliminary Report PNU-155971/9850135; February 1998 + Amendment of September 10, 1998/950240.
23. Colajori E. et al. Final Study Report 96-OEXE-031 *Randomized Double-blind Trial in Postmenopausal Women with Primary Breast Cancer who have Received Adjuvant Tamoxifen for 2-3 years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen*, dated 18 October 2004.
24. Pfizer Inc Aromasin *Clinical Overview Module 2.5*, dated 22 November 2004.
25. Reference deleted based on updated information added in CDS revision dated February 12, 2007.
26. Puperi L. Argentino-Storino A. Final Study Report No. 6539/T/327/2001.PNU-155971 (Exemestane) *24-Month Oral (Gavage) Carcinogenicity Study in the Mouse*, dated 16 July 2003.
27. Puperi L. Final Study Report No. 6538/T/294/2001. PNU-155971 (Exemestane) *24-Month Oral (Gavage) Carcinogenicity Study in the Rat*, dated 7 August 2003.
28. Brughera M. Exemestane (PNU-155971) Safety Assessment on Exemestane Carcinogenesis, dated 18 December 2003.
29. Subar M. et al. Study Report 971-ONC-0028-084 Randomized Phase II-III Study in First Line Hormonal Treatment for Metastatic Breast Cancer with Exemestane or Tamoxifen in Postmenopausal Patients, dated 30 November 2004.
30. Carpentieri M, Polli A. Interim Clinical Study Report A5991012-96-OEXE-031 (52-Month Median Follow-up) *Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen*, dated 16 October 2006.
31. Carpentieri M, Polli A. *Interim Full Clinical Study Report: Exemestane. Protocol Number: A5991012 – 96-OEXE-031 Bone Substudy (Full Results at 24 Months on Treatment). Randomized Double-Blind Trial in Postmenopausal Women with Primary Breast Cancer who have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen-Bone Sub-study (Full Results up to 24 Months on Treatment)*, dated 11 September 2006.
32. Carpentieri M, Polli A. Final Full Clinical Study Report A5991012-96-OEXE-31 Endometrial (1-year post treatment) *Randomized Double-blind Trial in Postmenopausal Women with Primary Breast Cancer who have Received Adjuvant Tamoxifen for 2-3 years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen*, dated 7 February 2006.
33. Pfizer Inc Aromasin *Clinical Overview Module 2.5*, dated 2 February 2007.
34. Reich L, Fajardo M. Clinical Overview. *Exemestane and Hepatitis. Safety & Risk Management*, Pfizer Inc. September 2008.
35. Module 2.5 Clinical Overview: *Exemestane; Adjuvant Treatment for Early Breast Cancer. Safety and Risk Management*, Pfizer Inc. May 2010.

36. Module 2.5 Clinical Overview. A Clinical Expert Report to Support Safety Revisions to the Exemestane Product Label (Vitamin D Assessment and Supplementation, and addition of ADRs pruritus, urticaria, and hypersensitivity). Pfizer Inc. May 2012.
37. Final Supplemental Clinical Study Report: Exemestane. Protocol Number: A5991012 96-OEXE-031 Supplemental (IES Bone). Randomized Double-Blind Trial in Postmenopausal Women with Primary Breast Cancer Who have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Treatment until 5 Years with Adjuvant Exemestane Versus Further Tamoxifen. Pfizer Inc. July 2009.
38. Module 2.5 Clinical Overview: Safety Updates to the Exemestane Core Data Sheet (AGEP and Paraesthesia). Pfizer Inc. September 2013.
39. Module 2.5 ADR Frequency and Category Clinical Overview. Pfizer Inc. September 2013.
40. Final Clinical Study Report: Exemestane, Protocol Number A 96-OEXE-031 (A5991012). *Randomized Double-Blind Trial in Postmenopausal Women with Primary Breast Cancer who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen.* Pfizer Inc. June 2014.
42. Module 2.4. Nonclinical Overview Exemestane. Pfizer Inc. January 2017.
43. Module 2.5 Clinical Overview to Support Update to Section 5.1 Pharmacodynamic Properties of the Core Data Sheet and National Label Update Based on the Final Results of the Intergroup Exemestane Study 96-OEXE-031 (A5991012). Pfizer Inc. August 2017

Document Approval Record

Document Name: LPD exemestane- Aromasin (Pakistan)

Document Title: LPD exemestane- Aromasin (Pakistan)

Signed By:	Date(GMT)	Signing Capacity
Patel, Bushra Muzamil	30-Jan-2018 06:31:14	Regulatory Affairs Approval